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summary 
The inhibition by opiates of the PGE2-induced formation of cAMP in 
slices from rat brain striatum was investigated. A maximal, 3.5- 
fold increase over the basal level of cAMP was obtained with an EC50 
for PGE 2 of 3 ~M. Opiate agonists of both ~ and < type were inhibi- 
tory. The IC50 values for morphine, levorphanol and ethylketocycla- 
zocine (EKC) were ii0 nM, 80 nM and 25 nM, respectively. These val- 
ues were similar to the potencies of the compounds in displacing 
stereospecifically bound 3H-etorphine in rat brain membranes. As 
evidencsdby the inactivity of dextrorphan, the inhibition of PGE 2- 
dependent cAMP formation was stereospecific. Also ineffective were 
the opiate antagonists naloxone, naltrexone and MR 2266. These com- 
pounds did, however, reverse the inhibition by agonists, displaying 
thereby selectivity toward the putative ~ and < opiates. Thus, the 
inhibition by morphine was antagonized to a greater degree by nalo- 
xone than by MR 2266, and the action of EKC was blocked more effec- 
tively by MR 2266 relative to naloxone. 
According to an attractive hypothesis, opiates exert some of their effects 
by modifying the intracellular concentration of cAMP. Original observations 
that opiates inhibited PGE-stimulated adenylate cyclase in brain homogenates 
(i) were difficult to replicate (2,3). However, in transformed cell lines from 
brain, an opiate sensitive basal and PGE-dependent adenylate cyclase were des- 
cribed (4), and the long-term maintenance of cellular cAMP levels by opiates 
was implicated in the phenomena of tolerance, dependence and withdrawal (5). 
The inhibition of basal adenylate cyclase in homogenates from normal brain was 
recently investigated (6). In slices from normal rat brain, opiates were shown 
to inhibit the PGE2-dependent increase of cAMP with partial reversal by na!oxon~ 
(7). We have previously reported the inhibition of PGE2-induced cAMP formation 
in slices from rat brain striatum, and the absence of that effect in primary 
cultures of astrocytes lacking opiates receptor (8). We now describe additional 
characteristics of the interaction of opiate with PGE2-dependent adenylate cy- 
clase in brain slices. Particular emphasis in this work was given to assess 
mediation of the phenomenon by opiate receptor, considering thereby its hetero- 
geneity (9). 
Materials and Methods 
The drugs used in this study were made available by the Drug Abuse Basic 
Research Program, The University of Michigan. MR 2266: (-)-e-5,9-diethyl-2- 
(3-furylmethyl)-2'-hydroxy-6,7-benzomorphan. PGE 2 was obtained from the Upjohn 
Co., Kalamazoo, MI., while 3H-cAMP and the radioassay kit for cAMP were 
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p~chased from the Amersham Corp., Arlington Heights, IL. Dowex resin and 
~-isobutyl-2-methylxanthine (IBMX) were obtained from Sigma Chem. Corp., St. 
Louis, MO. All other chemicals were of reagent grade. The buffer medium used 
throughout this work had the following composition (mM): NaCl, 125.0; KCI, 1.8; 
CaCI2, 1.3; MgS04, 1.2; KH2PO4, 1.2; NaHCO3, 25.0; glucose, i0; IBMX (phospho- 
diesterase inhibitor), 1.0. The pH of the buffer was adjusted to 7.4 by gassing 
with 95% 02 - 5% CO 2. A stock solution of 2.1 mg/100 ~i PGE 2 was prepared in 
95% ethanol. Further dilutions of this stock were made with the buffer medium. 
The first part of the methodology described below represents an adaptation 
of the procedure reported by Havemann and Kuschinsky (7). Male Sprague Dawley 
rats weighing 120-180 g were decapitated, the brains quickly excised and trans- 
ferred to 2-4 °. The striata were dissected and cut into 400 ~m slices using a 
McIlwain tissue chopper. The slices were suspended with 4 ml of buffer medium, 
and incubated for 15 min at 37 ° with 95% 02 - 5% CO 2 bubbling through the medi- 
um. At the end of each 5 minute period, 3.5 ml of the medium were removed and 
replaced by an identical aliquot of fresh 37 ° buffer. After the third wash, 
3.5 ml buffer containing PGE 2 (final concentration 35 ~M), or containing PGE 2 
and drug were added and the slices incubated for 5 min at 37 ° with gassing. 
The incubation was terminated by placing the samples in a boiling water bath 
for 5 min. In experiments with antagonists, the slices were first incubated in 
the presence of 35 ~M PGE 2 and i0 ~M antagonist for i0 min, then the agonist 
(final concentration i0 ~M) was added in a small vol~e of buffer, and the incu- 
bation continued for 5 min before termination by boiling. The contents of the 
vial were then disrupted for 1 min, using a Polytron homogenizer (Model P-10, 
Brinkman Instruments, Inc.) at the power output 6.5. In an aliquot of the 
homogenate, protein was determined according to Lowry et al. (i0). The remain- 
der of the homogenate was centrifuged at i0,000 x g for 15 min, and the super- 
natant removed and saved. The pellet was washed by resuspension for 30 sec 
using a Bronson Sonifier with microtip at power output 6, then centrifuged as 
described above. The two supernatants were combined, and an aliquot of 3H-cAMP 
(5000 cpm) was added to monitor recovery. After application to a Dowex ix2 
column (ii), the fractions containing 3H-cAMP were pooled and lyophilized. The 
samples were then reconstituted to the desired volume with 0.5 M Tris.HCl, pH 
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FIG. 1. PGE2-induced formation 
of cAMP. Striatal slices were 
incubated as described under Ma- 
terials and Methods for 5 min at 
37 ° in the absence and presence 
of PGE 2 as indicated. Control 
samples, without PGE 2, contained 
appropriate concentrations of 
ethanol, present in solutions of 
the prostaglandin, cAMP was ex- 
tracted and determined as des- 
cribed above. Each point is the 
mean of quadruplicate determina- 
tions. 
Results and Discussion 
PGE 2 increased the concentration of cAMP in striatal slices approximately 
3.5-fold, from 15.1 ± 2.7 pmole cAMP/mg protein in the control sample to the 
maximally stimulated value of 52.6 ± 8.6 pmole cAMP/mg protein. Maximal stimu- 
lation was obtained after 5 min incubation at 37 ° , with an EC50 for PGE 2 of 
approximately 3 ~M (Fig i). 
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FIG. 2. Inhibition of PGE2-induced 
cAMP formation. Striatal slices were 
incubated as described above with and 
without PGE 2 and I0 ~M of the com- 
pounds as indicated. Measured cAMP 
was expressed as pmole/mg protein. 
The inset shows log-probit plots of 
the inhibition obtained at several 
drug concentrations. Percent inhibi- 
tion was defined as 
(c~NPPGE - c~IPPGE+drug)  x 100 .  
(cAMPpG E - cAMPbasa l) 
Shown are mean values and standard 
deviations of 3-6 experiments. 
The PGE2-induced increase in cAMP levels was inhibited by putative ~ and < 
opiate agonists. The maximum effect leveled off below complete inhibition (Fig 
2). The inhibitory potency (Fig 2, inset) ranged from ii0 nM for morphine, to 
80 nM and 25 nM for levorphanol (not shown on the log-probit plot) and EKC. 
The magnitude and order of the ICS0 values were similar to those of the affini- 
ties of the agonists in binding to opiate receptor. The IC50 for morphine 
(12,13), levorphanol (12), and EKC (13) in displacing stereospecifically bound 
3H-etorphine in rat brain membranes, in the presence of 150 mM NaCI, were 142 
nM, 21 nM and 21 nM, respectively. Opiate antagonists of both p and < type did 
not inhibit the PGE2-induced cAMP formation. Also ineffective was dextrorphan, 
the pharmacologically inactive isomer of levorphanol (Fig 2), thus providing 
evidence for stereospecificity of the phenomenon. The receptor-related nature 
of the inhibition by opiate agonists of cAMP formation was also underlined by 
the ability of opiate antagonists, including naloxone, to block the inhibition 
by agonists (Fig 3). Furthermore, in the course of their antagonism these com- 
pounds displayed selectivity toward putative agonists of the ~ and < type. 
Thus, naloxone but not MR 2266, a benzomorphan antagonist (14), was effective 
in reversing the inhibitory effect of morphine. On the other hand, inhibition 
of cAMP formation by EKC, a putative < agonist (14,15) was antagonized to a 
significantly lesser degree by naloxone relative to MR 2266. A major obstacle 
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FIG. 3. Effect of antagonists on the 
inhibition of PGE2-induced cAMP forma- 
tion by opiate agonists. Striatal 
slices were incubated as described un- 
der Materials and Methods. The results 
shown were replicated twice, within 
one experiment each point was the mean 
of 4 determinations. 
in assessing opiate receptor heterogeneity is the equivocal specificity of the 
employed ligands, particularly as it relates to alkaloids of the < type. In 
view of the systematic evidence for dynorphin as a specific endogenous ligand 
for the putative < opiate receptor (16), it will be of interest to assess its 
effect on the functional relationship between receptor and putative effector, 
described here. 
Additional support for the mediation by opiate receptor of the investi- 
gated phenomenon was provided by the results obtained with isolated glial cells 
(8). Primary cultures of astrocytes from normal rat brain displayed virtually 
no opiate receptor binding. In these cells cAMP formation was stimulated 
20-fold by PGE2, but opiates were ineffective in inhibiting this increase. As- 
suming that glial cells are deficient in opiate receptor, the observed plateau 
in the inhibitory action of opiate agonists in brain slices (Fig i) becomes 
plausible. While the glial component of the tissue responds to PGE-stimulation 
of cAMP production, it is insensitive to opiate inhibition. In this respect 
our data disagree with the previously reported complete inhibition of the PGE- 
induced increase of cAMP in striatal slices (7). 
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